ArticleJournal of current ophthalmology
PRESERFLO MicroShunt Implantation as a Repeat Surgery after Failed Ab Interno XEN45 Gel Stent Implantation: A Case-Matched Study.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate through a case-matched analysis whether failed ab interno XEN45 Gel Stent implantation exerts an influence on the outcome after subsequent implantation of a Preserflo MicroShunt. Methods: In this retrospective study, 70 eyes from 70 participants who underwent Preserflo MicroShunt implantation were included. Thirty-five eyes each underwent primary stent implantation (control group) or had previously undergone failed XEN45 Gel Stent implantation (post-XEN group). The two groups were matched at a 1:1 ratio based on the following criteria: preoperative and maximum intraocular pressure (IOP), preoperative medication score, cup/disc-ratio, follow-up time, and age. Surgery was defined as either "success" or "failure" based on the following three scores: an IOP reduction of >20% and IOP at the longest follow-up <21 mmHg (Score A) or <18 mmHg (Score B) or IOP ≤15 mmHg and an IOP reduction ≥40% (Score C). In all scores, revision surgery was considered a failure. Furthermore, we compared postoperative IOP and medication score, side effects, and revision rate between both groups. Results: Mean IOP decreased from 28.9 to 12.2 mmHg in the post-XEN group and from 27.7 to 12.9 mmHg in the control group, while the mean medication score decreased from 2.1 in the post-XEN group and from 2.6 in the control group to 0.3, respectively. Comparative analyses between the two groups did not reveal a significant difference in postoperative IOP, medication score, side effects, revision, or success rate. Conclusion: Preserflo MicroShunt implantation can be considered a viable option for repeat surgery in patients with bleb failure after prior XEN45 Gel Stent implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.